The short version
Just 3 companies supply this market — thin enough that a single exit would be felt immediately.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Bupivacaine · BUPIVACAINE 13.3 mg/mL · Injection, Suspension, Liposomal · Infiltration · Jiangsu Hengrui Pharmaceuticals Co., Ltd.
NDC 57884-3252-01 · 10 VIAL in 1 CARTON / 20 mL in 1 VIAL · ANDA · View full market →
Just 3 companies supply this market — thin enough that a single exit would be felt immediately.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Not scored — fragility is computed for NADAC-priced NDCs.
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
No FDA shortage reports for this drug or its presentations.
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. | BUPIVACAINE 13.3 mg/mL | Jul 15, 2026 | Sep 3, 2026 |
| Pacira Pharmaceuticals, Inc. | BUPIVACAINE 13.3 mg/mL | Jul 15, 2026 | Sep 3, 2026 |
| Patheon UK Limited | BUPIVACAINE 13.3 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Bupivacaine — NDC 57884-3252-01," retrieved September 3, 2026, https://drugdashboards.com/drug/57884325201.
Free to cite with attribution — see how the data is put together.